Literature DB >> 8985079

Fibrin sealant reduces serous drainage and allows for earlier drain removal after axillary dissection: a randomized prospective trial.

M M Moore1, D H Nguyen, W D Spotnitz.   

Abstract

Fibrin sealant (FS) has been used successfully as an effective adhesive and hemostatic agent in a variety of surgical procedures. At the University of Virginia, autologous fibrin sealant is used to reduce the potential accumulation of serous fluid after axillary dissection in patients undergoing modified radical mastectomy (MRM) for carcinoma of the breast. Unilateral MRM, including level I and II axillary lymph node dissection, was performed upon 21 patients prospectively randomized into treatment and control groups. Surgical procedures between both groups differed only by the application of autologous FS prior to axilla closure in the treatment group. Drainage was collected and measured at 24-hour intervals following the operation. Drains were removed following the measurement of 40 ml or less during a 24-hour interval. Cumulative drainage for the first 3 postoperative days in the treatment group averaged 198 +/- 83 ml compared to 467 +/- 138 ml in the control group (P < 0.0003). Day of drain removal averaged 3.9 +/- 1.7 for the treatment group and 6.9 +/- 1.2 for the control group (P < 0.0001). In the treatment group, there was a reduction in cumulative drainage over the first 3 days of 268 ml or 57 per cent, and there was a reduction in the number of days before drains can be removed of 3.0 days, or 43 per cent. We conclude that local application of FS significantly reduced the total drainage measured in patients undergoing MRM and enabled earlier drain removal.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8985079

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  11 in total

Review 1.  Fibrin sealant: a review of its use in surgery and endoscopy.

Authors:  C J Dunn; K L Goa
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

2.  Effects of Fibrin Sealant on Seroma Reduction for Patients with Breast Cancer Undergoing Axillary Dissection: Meta-Analysis of Randomized Controlled Trials.

Authors:  Ya-Ting Chang; Shen-Liang Shih; El-Wui Loh; Ka-Wai Tam
Journal:  Ann Surg Oncol       Date:  2020-06-20       Impact factor: 5.344

3.  Ultrasonic shears versus electrocautery in axillary dissection for breast cancer-a randomized controlled trial.

Authors:  Suraj Manjunath; Rakesh S Ramesh; Shivakumar K; Vipin Goel
Journal:  Indian J Surg Oncol       Date:  2014-04-09

4.  Intraoperative application of fibrin sealant does not reduce the duration of closed suction drainage following radical axillary lymph node dissection in melanoma patients: a prospective randomized trial in 58 patients.

Authors:  Heiko Neuss; Wieland Raue; Gerold Koplin; Wolfgang Schwenk; Christian Reetz; Julian W Mall
Journal:  World J Surg       Date:  2008-07       Impact factor: 3.352

Review 5.  Fibrin glue instillation under skin flaps to prevent seroma-related morbidity following breast and axillary surgery.

Authors:  Muhammad S Sajid; Kristian H Hutson; Ignazio F Rapisarda; Riccardo Bonomi
Journal:  Cochrane Database Syst Rev       Date:  2013-05-31

6.  Efficacy of axillary exclusion on seroma formation after modified radical mastectomy.

Authors:  Mohammed Faisal; Sameh T Abu-Elela; Waleed Mostafa; Osama Antar
Journal:  World J Surg Oncol       Date:  2016-02-20       Impact factor: 2.754

7.  Seroma formation after breast cancer surgery: what we have learned in the last two decades.

Authors:  Vivek Srivastava; Somprakas Basu; Vijay Kumar Shukla
Journal:  J Breast Cancer       Date:  2012-12-31       Impact factor: 3.588

8.  Efficacy and safety of fibrin sealant for tissue adherence in facial rhytidectomy.

Authors:  William D Spotnitz
Journal:  Clin Cosmet Investig Dermatol       Date:  2012-05-24

9.  Fibrin sealant does not decrease seroma output or time to drain removal following inguino-femoral lymph node dissection in melanoma patients: a randomized controlled trial (NCT00506311).

Authors:  Melinda M Mortenson; Yan Xing; Storm Weaver; Jeffrey E Lee; Jeffrey E Gershenwald; Anthony Lucci; Paul F Mansfield; Merrick I Ross; Janice N Cormier
Journal:  World J Surg Oncol       Date:  2008-06-18       Impact factor: 2.754

Review 10.  Fibrin Sealant: The Only Approved Hemostat, Sealant, and Adhesive-a Laboratory and Clinical Perspective.

Authors:  William D Spotnitz
Journal:  ISRN Surg       Date:  2014-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.